413 related articles for article (PubMed ID: 34547581)
21. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
[TBL] [Abstract][Full Text] [Related]
22. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
[TBL] [Abstract][Full Text] [Related]
23. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
24. Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.
Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Kashiwagi S; Maeda K; Hirakawa K; Ohira M
Anticancer Res; 2020 Jul; 40(7):4157-4163. PubMed ID: 32620665
[TBL] [Abstract][Full Text] [Related]
25. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
Yoshino T; Oki E; Nozawa H; Eguchi-Nakajima T; Taniguchi H; Morita S; Takenaka N; Ozawa D; Shirao K
ESMO Open; 2018; 3(5):e000411. PubMed ID: 30167332
[TBL] [Abstract][Full Text] [Related]
27. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
[TBL] [Abstract][Full Text] [Related]
28. Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment.
Fujimoto Y; Oki E; Qiu S; Nakanishi R; Makiyama A; Miyamoto Y; Kotaka M; Shimokawa M; Ando K; Kimura Y; Kitao H; Maehara Y; Mori M
Cancer Sci; 2021 Jun; 112(6):2436-2441. PubMed ID: 33780084
[TBL] [Abstract][Full Text] [Related]
29. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
31. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Kuboki Y; Watanabe J; Terazawa T; Kawakami H; Yokota M; Nakamura M; Kotaka M; Sugimoto N; Ojima H; Oki E; Kajiwara T; Yamamoto Y; Tsuji Y; Denda T; Tamura T; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Target Oncol; 2024 Jan; 19(1):59-69. PubMed ID: 38194163
[TBL] [Abstract][Full Text] [Related]
32. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
[TBL] [Abstract][Full Text] [Related]
33. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
[TBL] [Abstract][Full Text] [Related]
34. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
[TBL] [Abstract][Full Text] [Related]
37. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.
Samawi HH; Brezden-Masley C; Afzal AR; Cheung WY; Dolley A
Curr Oncol; 2019 Oct; 26(5):319-329. PubMed ID: 31708650
[TBL] [Abstract][Full Text] [Related]
38. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
Doleschal B; Taghizadeh H; Lentner T; Riedl JM; Granitzer J; Morariu D; Decker J; Aichberger KJ; Webersinke G; Kirchweger P; Petzer A; Rumpold H
ESMO Open; 2023 Dec; 8(6):102064. PubMed ID: 37977001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
